Physician profile
Paul Cullis
NPI 1285664680
$5,997.84
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,314 · 2020: $2,227 · 2021: $1,304 · 2023: $138 · 2024: $15.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $520.10 | 2019-2021 | |
| Biogen, INC. | $506.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $500.58 | 2019-2021 | |
| Ucb, INC. | $390.40 | 2019-2021 | |
| Genzyme Corporation | $320.48 | 2019-2020 | |
| Emd Serono, INC. | $310.40 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $283.01 | 2019-2021 | |
| Mdd US Operations, LLC | $274.30 | 2019-2021 | |
| Greenwich Biosciences, INC. | $251.63 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $247.05 | 2019-2021 | |
| Amgen INC. | $214.98 | 2019-2021 | |
| Medtronic USA, INC. | $164.67 | 2019-2020 | |
| Eisai INC. | $162.40 | 2019-2020 | |
| Genentech USA, INC. | $159.75 | 2019-2020 | |
| Acorda Therapeutics, INC | $129.72 | 2019 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cullis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.